|
Report Date : |
31.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
NEUTRO PHARMA (PVT.) LIMITED |
|
|
|
|
Registered Office : |
9.5 Km,
Sheikhupura Road, Lahore |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Incorporation : |
1998 |
|
|
|
|
Com. Reg. No.: |
0044741 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture &
Import of Pharmaceuticals & Neutraceutical Medicine |
|
|
|
|
No. of Employees : |
126 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
PAKISTAN - ECONOMIC OVERVIEW
Decades of internal political disputes and low levels of
foreign investment have led to slow growth and underdevelopment in Pakistan.
Agriculture accounts for more than one-fifth of output and two-fifths of
employment. Textiles account for most of Pakistan's export earnings, and
Pakistan's failure to expand a viable export base for other manufactures has
left the country vulnerable to shifts in world demand. Official unemployment is
under 6%, but this fails to capture the true picture, because much of the
economy is informal and underemployment remains high. Over the past few years,
low growth and high inflation, led by a spurt in food prices, have increased
the amount of poverty - the UN Human Development Report estimated poverty in
2011 at almost 50% of the population. Inflation has worsened the situation,
climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in
2012. As a result of political and economic instability, the Pakistani rupee
has depreciated more than 40% since 2007. The government agreed to an
International Monetary Fund Standby Arrangement in November 2008 in response to
a balance of payments crisis. Although the economy has stabilized since the
crisis, it has failed to recover. Foreign investment has not returned, due to
investor concerns related to governance, energy, security, and a slow-down in
the global economy. Remittances from overseas workers, averaging about $1
billion a month since March 2011, remain a bright spot for Pakistan. However,
after a small current account surplus in fiscal year 2011 (July 2010/June
2011), Pakistan's current account turned to deficit in fiscal year 2012,
spurred by higher prices for imported oil and lower prices for exported cotton.
Pakistan remains stuck in a low-income, low-growth trap, with growth averaging
about 3% per year from 2008 to 2012. Pakistan must address long standing issues
related to government revenues and energy production in order to spur the
amount of economic growth that will be necessary to employ its growing and
rapidly urbanizing population, more than half of which is under 22. Other long
term challenges include expanding investment in education and healthcare,
adapting to the effects of climate change and natural disasters, and reducing
dependence on foreign donors.
Source
: CIA
NEUTRO PHARMA
(PVT.) LIMITED
|
Registered Address & Factory |
|
9.5 Km,
Sheikhupura Road, Lahore, Pakistan |
|
Tel # |
92 (42) 37915786,
37915787, 37915788, 37915789, 37915790 |
|
Fax # |
92 (42) 37915791 |
|
Email |
|
a. |
Nature of Business |
Manufacture & Import of Pharmaceuticals & Neutraceutical
Medicine |
|
b. |
Year Established |
1998 |
|
c. |
Registration No. |
0044741 |
In
Karachi & Rawalpindi
|
Arshad & Co. (Chartered Accountants) 102-Nawab Plaza, 48-Main Shadman Market, Lahore, Pakistan |
|
Subject Company was established as a Private Limited Company in 1998 |
|
6. |
Authorized Capital |
Rs. 10,000,000
divided into 100,000 shares of Rs. 100/- each |
|
|
Issued & Paid up Capital |
Rs. 10,000,000
divided into 100,000 shares of Rs.100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Hamid Raza Mr. Amir Raza Mrs. Sarwat Hamid |
Pakistani Pakistani Pakistani |
9.5 Km, Sheikhupura Road, Lahore 9.5 Km, Sheikhupura Road, Lahore 9.5 Km, Sheikhupura Road, Lahore |
Business Business Business |
Chief Executive Director Director |
|
Names |
No. of Shares |
|
Mr. Hamid Raza Mr. Amir Raza Mrs. Sarwat Hamid |
70,000 15,000 15,000 |
A. Subsidiary
None
B. Associated
Companies
(1)
Shaf Pharmaceuticals, Pakistan.
(2)
Adnan Traders, Pakistan.
(3)
Darex Pharma., Pakistan.
(1) PRINSEN B.V., HOLLAND.
(2) SCHILLS FOOD, HOLLAND.
(3) DONGKOO PHARMACEUTICALS CO., LTD, KOREA.
(4) DIA HAN PHARMACEUTICALS CO., LTD, KOREA.
(5) UNIMED PHARMACEUTICALS
INCORPORATED, KOREA.
(6) WAKAMOTO PHARMACEUTICALS CO. LTD, JAPAN.
(7) BOUCHARA RECORDITI, FRANCE.
(8) I.C. PRODUCTS, SWITZERLAND.
(9) MASS PHARMA. (PVT) LTD., PAKISTAN.
(10) P.D.H PHARMACEUTICALS (PVT) LTD.,
PAKISTAN.
(11) POPULAR CHEMICAL WORKS (PVT) LTD.,
PAKISTAN.
(12) XENON PHARMACEUTICALS (PVT) LTD.,
PAKISTAN.
|
NEUTRACEUTICALS: Setpoint Diet Starter Pack Low
Calorie Diet For treatment of obesity
(Beginners pack). Setpoint Diet Low Calorie Diet For treatment of obesity (Regular
use pack). Supplement-M
Starter Pack Special
Nutritional formula for pregnant women Supplement-M Special
nutritional formula for
Lactating mothers. Moducal High
calorie balance diet for patients in hyper catabolic state. Glucotrol Therapeutic
nutrition for Diabetics. |
|
|
|
PHARMACEUTICALS: Indrop-D Inj/Oral Cholecalciferol. Neutrocyn Doxycycline. Famodine 20 Famotidine 20 mg tabs. Famodine 40 Famotidine 40 mg. Newsadal Norfloxacin. Kite Ketamine Inj. Socin 1gm Ceftriaxone Sodium inj 1 gm. Socin 500 mg Ceftriaxone Sodium inj 500 mg. Socin 250 mg Ceftriaxone Sodium inj 250 mg. Gynosept Disinfectant Solution for
gynecological
Procedures. Fermacidal Disinfectant solution for
general
Procedures. OTHERS: Hico Vasoactive agent. Leberplant Hepatoprotective and
Hepatoregenerative
Agent with silimarin. |
|
SERVICES: 1.
Audiocassettes programs for obese patients to
guide them for effective weight loss program. 2.
Audiocassettes programs for pregnants to guide
them for health pregnancy. 3.
Audio program for a.
Modern
concepts in selling b.
Personal grooming c.
Objection handling d.
Closing skills 4. Medical journal (In process). |
126
The capacity and
production of the company’s plant is indeterminable as it is multi-product and
involves varying processes of manufacture.
|
Years |
In Pak Rupees |
|
2012 |
150,000,000/- (Estimated) |
|
Mainly Distribution Companies, Pharmacies,
Retailers, Wholesalers etc |
|
(1) Habib Bank
Limited, Pakistan. (2) Bank Alfalah
Limited, Pakistan. (3) MCB Bank Limited,
Pakistan. (4) Allied Bank
Limited, Pakistan. |
·
Lahore Chamber of
Commerce & Industry.(LCCI)
|
Currency |
Unit |
Pakistani Rupees |
|
US Dollar |
1 |
Rs. 104.00 |
|
UK Pound |
1 |
Rs. 161.00 |
|
Euro |
1 |
Rs. 138.25 |
Subject Company
was established in 2002 and is engaged in manufacture & import of Pharmaceuticals & Neutraceutical
Medicine. Directors are reported as qualified, experienced and resourceful
businessmen. Trade relations are reported as fair. Subject can be considered
for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.57 |
|
|
1 |
Rs.103.34 |
|
Euro |
1 |
Rs.88.16 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.